Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Raspberry Pi interim profits slide on tough comparatives

(Sharecast News) - High-performance computing firm Raspberry Pi reported a drop in both revenue and profits for the first half of 2025, as it cycled through tough comparatives following last year's Raspberry Pi 5 launch. Raspberry Pi said royalty and component sales were lower year-on-year, leading to a 6% decline in revenue to $133.5m, while adjusted underlying earnings fell 7% to $19.4m and pre-tax profits sank 43% to $6.2m. On the other hand, gross margins improved slightly ticking up by one percentage point to 25%.

The London-listed firm cited a return to more normalised market dynamics and a shift in product mix as key factors behind the softer top-line performance.

Despite the headline decline, Raspberry Pi pointed to strong operational progress, with direct sales of single-board computers and Compute Modules rising, offsetting weaker licensee volumes. Semiconductor shipments overtook board volumes for the first time, driven by robust demand for RP2040 and RP2350 microcontrollers.

Raspberry Pi stated momentum had continued to build across direct-to-reseller and OEM channels, with a growing pipeline of design wins and a substantial order backlog and highlighted that it was well-positioned to manage dynamic random-access memory price volatility, with sufficient supply on hand.

It also reiterated full-year profit guidance and noted that H2 had started well, with EBITDA ahead of the same period last year.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.